Brk Antibody (5G1): sc-66003

Brk Antibody (5G1) is a mouse monoclonal IgG1 antibody that detects Brk in human samples through applications such as western blotting (WB) and immunoprecipitation (IP). Brk, also known as breast tumor kinase or PTK6, is a non-receptor tyrosine kinase that plays a pivotal role in various cellular processes, including cell proliferation, survival, and motility, by modulating ligand-mediated signal transduction pathways. Brk is primarily located in epithelial tissues, specifically in the cell layers just above the proliferative zone in the skin and the lining of the alimentary canal, which is crucial for maintaining tissue integrity and function. Notably, Brk is expressed at high levels in the colon, small intestine, and prostate, while Brk expression is significantly upregulated in many breast carcinomas, making Brk a potential biomarker for cancer diagnosis and prognosis. Brk′s ability to undergo autophosphorylation is particularly important, as this process may influence activity and regulatory mechanisms, further underscoring Brk′s significance in cancer biology. With specific reactivity and robust performance in key applications, anti-Brk antibody (5G1) is an essential tool for researchers investigating this kinase in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Brk Antibody (5G1) References:

1. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases.  |  Serfas, MS. and Tyner, AL. 2003. Oncol Res. 13: 409-19. PMID: 12725532
2. Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage.  |  Harvey, AJ., et al. 2009. Am J Pathol. 175: 1226-34. PMID: 19661439
3. Brk/PTK6 signaling in normal and cancer cell models.  |  Ostrander, JH., et al. 2010. Curr Opin Pharmacol. 10: 662-9. PMID: 20832360
4. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.  |  Locatelli, A., et al. 2012. Horm Cancer. 3: 14-25. PMID: 22124844
5. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.  |  Regan Anderson, TM., et al. 2013. Cancer Res. 73: 5810-20. PMID: 23928995
6. Tracing the footprints of the breast cancer oncogene BRK - Past till present.  |  Goel, RK. and Lukong, KE. 2015. Biochim Biophys Acta. 1856: 39-54. PMID: 25999240
7. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.  |  Jiang, J., et al. 2017. Cancer Res. 77: 175-186. PMID: 27758886
8. Putting the BRK on breast cancer: From molecular target to therapeutics.  |  Ang, HL., et al. 2021. Theranostics. 11: 1115-1128. PMID: 33391524
9. BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1.  |  Mandapati, A., et al. 2023. Cell Signal. 108: 110723. PMID: 37216999
10. ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis.  |  Guillet, S., et al. 2024. Elife. 13: PMID: 39570652

The preferred Brk antibody is Brk Antibody (D-7): sc-137045.